Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
ANNAPOLIS, MD, UNITED STATES, January 29, 2026 /EINPresswire.com/ — RadSite™, a leading accreditation agency promoting safety and quality in imaging, will host a ...
ANNAPOLIS, MD, UNITED STATES, February 17, 2026 /EINPresswire.com/ — RadSite™, a leading accreditation agency promoting safety and quality in imaging, will host a ...
Therapeutic management of locally advanced, recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is often limited by a rather unfavorable efficacy and toxicity ratio. Since the 1990s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results